Wuhan YZY Biopharma Co (HKSE:02496) 3-Year Share Buyback Ratio : -0.10% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Wuhan YZY Biopharma Co 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Wuhan YZY Biopharma Co's current 3-Year Share Buyback Ratio was -0.10%.

The historical rank and industry rank for Wuhan YZY Biopharma Co's 3-Year Share Buyback Ratio or its related term are showing as below:

HKSE:02496' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -0.1 Med: -0.1 Max: -0.1
Current: -0.1

During the past 4 years, Wuhan YZY Biopharma Co's highest 3-Year Share Buyback Ratio was -0.10%. The lowest was -0.10%. And the median was -0.10%.

HKSE:02496's 3-Year Share Buyback Ratio is ranked better than
93.71% of 1287 companies
in the Biotechnology industry
Industry Median: -10.3 vs HKSE:02496: -0.10

Competitive Comparison of Wuhan YZY Biopharma Co's 3-Year Share Buyback Ratio

For the Biotechnology subindustry, Wuhan YZY Biopharma Co's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wuhan YZY Biopharma Co's 3-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Wuhan YZY Biopharma Co's 3-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Wuhan YZY Biopharma Co 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Wuhan YZY Biopharma Co (HKSE:02496) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Wuhan YZY Biopharma Co 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Wuhan YZY Biopharma Co's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan YZY Biopharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan YZY Biopharma Co Ltd (HKSE:02496) » Definitions » 3-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 666 Gaoxin Road, East Lake High Tech, Development Zone, Hubei Province, Wuhan, CHN

Website

https://en.yzybio.com

Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody-based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing a new class of medicines in respect to anti-tumor bispecific antibody. It generates the majority of its revenue from PRC.

Executives

Wen Zhicheng	2201 Interest of corporation controlled by you
Guo Hong Wei
Dragon Merit Holdings Limited	2201 Interest of corporation controlled by you
Shi Yao Ji Tuan En Bi Pu Yao Ye You Xian Gong Si	2101 Beneficial owner
Cspc Pharmaceutical Group Limited	2201 Interest of corporation controlled by you
Robust Sun Holdings Limited	2201 Interest of corporation controlled by you
Wang Hongjie	2201 Interest of corporation controlled by you
He Bei Yi Er Qi Ye Guan Li Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Mei Shan Bao Shui Gang Qu Guang Rui Hong Xiang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Guo Xin Si Chuang Tou Zi Ji Jin Guan Li Bei Jing You Xian Gong Si	2201 Interest of corporation controlled by you
Nan Jing Cai Zhi Er Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Cdh 2018 Vgc Investment Fund, L.p.	2201 Interest of corporation controlled by you
Nan Ning Hui You Xing Yao Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Nan Ning Yao You Shang Wu Zi Xun He Huo Qi Ye You Xian He Huo
Wen Zhi Cheng

Wuhan YZY Biopharma Co Headlines

No Headlines